Reilly T P, MacArthur R D, Farrough M J, Crane L R, Woster P M, Svensson C K
Department of Pharmaceutical Sciences, Department of Internal Medicine, Wayne State University, Detroit, Michigan 48202, USA.
J Pharmacol Exp Ther. 1999 Dec;291(3):1356-64.
Hypersensitivity (HS) reactions to sulfonamides and sulfones continue to limit their use in human immunodeficiency virus (HIV)-infected individuals. In vitro cytotoxicity of hydroxylamine metabolites toward peripheral blood mononuclear cells (PBMCs) has been proposed as a marker for these HS reactions. To test the validity of this in vitro system, we determined the selective susceptibility of PBMCs from HIV-infected patients to the cytotoxic effects of hydroxylamine metabolites of sulfamethoxazole (SMX) and dapsone (DDS). Concentration-cytotoxic response data were collected using PBMCs from 12 sulfa-HS (10 SMX-HS and 2 SMX/DDS-HS) and 10 sulfa-tolerant HIV-infected individuals. Although sulfamethoxazole hydroxylamine (SMX-NOH) and dapsone hydroxylamine (DDS-NOH) both caused concentration-dependent increases in cell death, DDS-NOH was significantly more potent in each subject (P <.0001). A comparison of a variety of mean data for sulfa-HS and -tolerant patient populations failed to demonstrate the increased susceptibility of PBMCs from HS patients, noted by others, to either SMX-NOH or DDS-NOH. Moreover, any trend toward an increased susceptibility of PBMCs from HS patients was eliminated when adjusted for control cell death. PBMCs from sulfa-HS patients showed significantly greater susceptibility to the stress of short term in vitro incubation (P <. 02). Mean (S.D.) vehicle control cell death values were 24.1% (7.6%) for HS patients and 17.1% (4.4%) for tolerant patients. No significant correlation was observed between hydroxylamine-induced or control cell death and any of the recorded clinical parameters. Although several potential reasons are proposed to explain the disparity with past investigations, the data suggest that in vitro cytotoxicity is not a valid marker for HS reactions in HIV-infected individuals using currently accepted experimental procedures.
对磺胺类药物和砜类药物的超敏反应(HS)持续限制了它们在人类免疫缺陷病毒(HIV)感染个体中的应用。有人提出羟胺代谢产物对外周血单个核细胞(PBMC)的体外细胞毒性可作为这些HS反应的一个标志物。为了检验该体外系统的有效性,我们测定了HIV感染患者的PBMC对磺胺甲恶唑(SMX)和氨苯砜(DDS)羟胺代谢产物细胞毒性作用的选择性敏感性。使用来自12名磺胺类药物超敏反应患者(10名SMX超敏反应患者和2名SMX/DDS超敏反应患者)以及10名磺胺类药物耐受的HIV感染个体的PBMC收集浓度-细胞毒性反应数据。尽管磺胺甲恶唑羟胺(SMX-NOH)和氨苯砜羟胺(DDS-NOH)均导致细胞死亡呈浓度依赖性增加,但在每个受试者中DDS-NOH的效力显著更高(P<.0001)。对磺胺类药物超敏反应患者和耐受患者群体的各种平均数据进行比较,未能证明如其他人所指出的超敏反应患者的PBMC对SMX-NOH或DDS-NOH的易感性增加。此外,在对对照细胞死亡进行校正后,超敏反应患者的PBMC易感性增加的任何趋势均被消除。磺胺类药物超敏反应患者的PBMC对短期体外培养应激的敏感性显著更高(P<.02)。超敏反应患者的平均(标准差)溶媒对照细胞死亡值为24.1%(7.6%),耐受患者为17.1%(4.4%)。未观察到羟胺诱导的或对照细胞死亡与任何记录的临床参数之间存在显著相关性。尽管提出了几个潜在原因来解释与既往研究的差异,但数据表明,使用目前公认的实验程序时,体外细胞毒性并非HIV感染个体中HS反应的有效标志物。